biote Corp.: insider trades · United States · SEC (Form 4)

About biote Corp.

biote Corp. (NASDAQ: BTMD) is a U.S.-based healthcare company focused on hormone optimization and therapeutic wellness, with a business model that is best described as a practitioner-enablement platform. Headquartered in Irving, Texas, in the United States, the company was founded in 2012 and built its franchise around the Biote Method, a proprietary form of bioidentical hormone replacement therapy (BHRT) delivered through subcutaneous pellet insertion. For investors, biote should be viewed as a niche health-care platform tied to preventive care, age-management medicine, and the broader secular demand for personalized wellness solutions. The company’s business model has two main pillars. First, biote trains and supports Biote Certified Providers — physicians, nurse practitioners, and other clinicians — so they can deliver the company’s hormone optimization protocol in their own practices. Second, biote commercializes the products and support infrastructure that surround that protocol, including bioidentical hormone pellets, dietary supplements, and practice-support tools. The company also emphasizes software and workflow support, including BioTracker, which helps practices manage orders, inventory, and related administrative processes. In effect, biote is not just selling a product; it is building an integrated clinical ecosystem that helps physicians launch and scale hormone-optimization services. From a competitive standpoint, biote differentiates itself through its provider network, standardized clinical method, and end-to-end practice support. The company states that it has expanded to thousands of certified providers across the U.S., giving it a meaningful footprint in a category that remains relatively fragmented. Its positioning is supported by the appeal of in-office treatment, recurring patient engagement, and a highly targeted demographic seeking solutions for symptoms linked to hormonal imbalance and healthy aging. At the same time, the business operates in a competitive and heavily regulated environment, where success depends on physician adoption, patient retention, manufacturing reliability, and careful regulatory compliance. Recent developments are especially relevant. In 2025 and into early 2026, biote highlighted an organizational restructuring, the phased launch and expansion of BioteRx, and vertical integration of its 503B manufacturing capability to improve control and margin economics. The company has also been working to broaden its commercial reach and strengthen new clinic growth. Most recently, management reported in first-quarter 2026 results that certain hormone pellet products were subject to a voluntary recall, creating temporary supply constraints and pressuring procedure revenue in the near term. That means the investment case in BTMD currently combines attractive secular growth exposure with operational execution risk, supply-chain sensitivity, and regulatory complexity typical of specialty health-care models.